Clinical adjudication in acute kidney injury studies: findings from the pivotal TIMP-2*IGFBP7 biomarker study
OPEN Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 28 Jun 2016
KD Liu, A Vijayan, MH Rosner, J Shi, LS Chawla and JA Kellum
The NEPROCHECK test (Astute Medical, San Diego, CA, USA) combines urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) to identify patients at high risk for acute kidney injury (AKI). In a US Food and Drug Administration registration trial (NCT01573962), AKI was determined by a three-member clinical adjudication committee. The objectives were to examine agreement among adjudicators as well as between adjudicators and consensus criteria for AKI and to determine the relationship of biomarker concentrations and adjudicator agreement.
* Data courtesy of Altmetric.com